Sensitivity analyses focusing exclusively on GLP-1 RAs showed consistent results, with a 44% reduction in the risk of reaching the composite IBD outcome (adjusted IRR: 0.56, 95% CI: 0.39–0.83). The gene discussed is GLP1R; the disease is inflammatory bowel disease.